INNATE PHARMA : clinical data featured as oral presentations at two major upcoming oncology conferences

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites.
Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. For avoidance of any doubts and to make it easier, you may consider any links to external websites as sponsored links. Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

INNATE PHARMA CLINICAL DATA FEATURED AS ORAL PRESENTATIONS AT TWO MAJOR UPCOMING ONCOLOGY CONFERENCES

  • Late-breaking abstract and oral presentation on clinical and translational biomarker results from the combination of monalizumab and cetuximab in R/M SCCHN at the SITC 2018 Annual Meeting
  • Oral presentation of updated data from Phase I of IPH4102 in patients with relapsed/refractory Sézary Syndrome at the ASH 2018 Annual Meeting

Marseille, France, November 2, 2018, 07:00 AM CET

Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announced that new data from ongoing clinical trials evaluating monalizumab, partnered with AstraZeneca/MedImmune, and first-in-class antibody, IPH4102, will be presented at the SITC[1] 2018 Annual Meeting in Washington D.C., USA, November 7-11, 2018 and at ASH[2] 2018 Annual Meeting in San Diego, USA, December 1-4, 2018, respectively.

SITC 2018:

  • Title: monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results
  • Date and time: November 11, 2018, 9:05 am
  • Session: Clinical Trials Session 302
  • Presenter: Roger Cohen, Principal Investigator and Prof. of Medicine at the Hospital of the University of Pennsylvania
  • Location: 202 AB, Walter E. Washington Convention Center, Washington, D.C., USA

   ASH 2018:

  • Title: IPH4102; an anti-KIR3DL2 monoclonal antibody in refractory Sézary Syndrome: Results from a multicenter phase 1 trial
  • Date and time: December 3, 2018, 11:45 am
  • Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Immunotherapy and Targeted Strategies.
  • Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
  • Location: San Diego Convention Center, Room 6F, San Diego, USA

Innate Pharma is also taking part in many other scientific congresses, listed below:

  • 13th Annual Meeting of Chinese Society for Immunology, Shanghai, China, from November 7 to November 11, 2018
  • PEGS Europe 2018, Lisbon, Portugal, from November 12 to November 16, 2018
  • 4th ICI Europe Summit, Berlin, Germany, from November 27 to November 29, 2018
  • 3rd International Conference on Innate Lymphoid Cells, Tokyo, Japan, from November 29 to December 1st, 2018

For the full schedule of each event, please visit the “Events” section on Innate Pharma’s website.

About Innate Pharma:

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune. 

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com.

Information about Innate Pharma shares:

ISIN code Ticker code LEI FR0010331421 IPH 9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors   Innate Pharma  Dr. Markus Metzger / Danielle Spangler / Jérôme Marino Tel.: +33 (0)4 30 30 30 30 [email protected]   International Media   Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700 [email protected]
  French Media   ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 [email protected]  

[1] Society for Immunotherapy of Cancer

[2] American Society of Hematology

Attachment

INNATE PHARMA : clinical data featured as oral presentations at two major upcoming oncology conferences 1